The Tisch Cancer Institute | Strategic Alliance Partners

Latest from The Tisch Cancer Institute

Mount Sinai’s Natasha Kyprianou, MBBS, PhD, to Receive American Urological Association’s Richard D. Williams, MD, Prostate Cancer Research Excellence Award

May 26, 2022

Mount Sinai researcher Natasha Kyprianou, MBBS, PhD, a leading expert on prostate, bladder, and kidney cancer, has been awarded the Richard D. Williams, MD, Prostate Cancer Research Excellence Award by the Urology Care Foundation, the world’s leading nonprofit urological health foundation and official foundation of the American Urological Association.

Nivolumab Offers Long-Term DFS Benefits in Urothelial Carcinoma

May 14, 2022

According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.

Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma

May 04, 2022

Most immunocompromised people with multiple myeloma benefited from a third dose of COVID-19 vaccines. However, some people with multiple myeloma still remained vulnerable and may need a fourth dose or antibody treatments as restrictions lift and new variants emerge

FDA Approval of Cilta-Cel Fast Tracks Multiple Myeloma Toward Curative Potential

March 07, 2022

Sundar Jagannath, MBBS, discusses the significance of the FDA approval of ciltacabtagene autoleucel, important adverse effects to be aware of, and shared his thoughts on where the treatment fits into the current and future treatment paradigms.

Bispecific Antibodies Show Potential After Relapse on CAR T-cell Therapy in Myeloma

March 02, 2022

Oliver Van Oekelen, MD, MSc, discusses findings from a retrospective study that evaluated treatment and efficacy outcomes in patients with relapsed or refractory multiple myeloma who experienced disease progression after BCMA-directed CAR T-cell therapy.

Mount Sinai and Samuel Waxman Cancer Research Foundation to Collaborate Against the Rising Incidence of Cancer Due to Aging

February 09, 2022

The Tisch Cancer Institute at Mount Sinai and the Samuel Waxman Cancer Research Foundation are launching a unique research program that will fund collaborations between TCI physician-scientists and colleagues from other established cancer research institutions to address the rising rates of cancer due to aging around the world.

Subcutaneous Daratumumab Plus Kd Is a “Gamechanger” for Patients With Multiple Myeloma

January 24, 2022

Ajai Chari, MD, reviews the takeaways from the PLEIADES trial and its comparability with the CANDOR trial, and how a subcutaneous formulation of a daratumumab combination became a pivotal player in the treatment enhancement for patients with relapsed or refractory multiple myeloma.